Literature DB >> 28919249

Dosimetric predictors for acute esophagitis during radiation therapy for lung cancer: Results of a large statewide observational study.

Peter Paximadis1, Matthew Schipper2, Martha Matuszak2, Mary Feng2, Shruti Jolly2, Thomas Boike3, Inga Grills4, Larry Kestin5, Benjamin Movsas6, Kent Griffith2, Gregory Gustafson4, Jean Moran2, Teamour Nurushev5, Jeffrey Radawski7, Lori Pierce2, James Hayman2.   

Abstract

PURPOSE: The purpose of this study is to identify dosimetric variables that best predict for acute esophagitis in patients treated for locally advanced non-small cell lung cancer in a prospectively accrued statewide consortium. METHODS AND MATERIALS: Patients receiving definitive radiation therapy for stage II-III non-small cell lung cancer within the Michigan Radiation Oncology Quality Consortium were included in the analysis. Dose-volume histogram data were analyzed to determine absolute volumes (cc) receiving doses from 10 to 60 Gy (V10, V20, V30, V40, V50, and V60), as well as maximum dose to 2 cc (D2cc), mean dose (MD), and generalized equivalent uniform dose (gEUD). Logistic regression models were used to characterize the risk of toxicity as a function of dose and other covariates. The ability of each variable to predict esophagitis, individually or in a multivariate model, was quantified by receiver operating characteristic analysis.
RESULTS: There were 533 patients who met study criteria and were included; 437 (81.9%) developed any grade of esophagitis. Significant variables on univariate analysis for grade ≥2 esophagitis were concurrent chemotherapy, V20, V30, V40, V50, V60, MD, D2cc, and gEUD. For grade ≥3 esophagitis, the predictive variables were: V30, V40, V50, V60, MD, D2cc, and gEUD. In multivariable modeling, gEUD was the most significant predictor of both grade ≥2 and grade ≥3 esophagitis. When gEUD was excluded from the model, D2cc was selected as the most predictive variable for grade ≥3 esophagitis. For an estimated risk of grade ≥3 esophagitis of 5%, the threshold values for gEUD and D2cc were 59.3 Gy and 68 Gy, respectively.
CONCLUSIONS: In this study, we report the novel finding that gEUD and D2cc, rather than MD, were the most predictive dose metrics for severe esophagitis. To limit the estimated risk of grade ≥3 esophagitis to <5%, thresholds of 59.3 Gy and 68 Gy were identified for gEUD and D2cc, respectively.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 28919249      PMCID: PMC6818411          DOI: 10.1016/j.prro.2017.07.010

Source DB:  PubMed          Journal:  Pract Radiat Oncol        ISSN: 1879-8500


  27 in total

1.  Predictors of severe esophagitis include use of concurrent chemotherapy, but not the length of irradiated esophagus: a multivariate analysis of patients with lung cancer treated with nonoperative therapy.

Authors:  M Werner-Wasik; E Pequignot; D Leeper; W Hauck; W Curran
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-10-01       Impact factor: 7.038

2.  Use of normal tissue complication probability models in the clinic.

Authors:  Lawrence B Marks; Ellen D Yorke; Andrew Jackson; Randall K Ten Haken; Louis S Constine; Avraham Eisbruch; Søren M Bentzen; Jiho Nam; Joseph O Deasy
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-03-01       Impact factor: 7.038

3.  Recommendations from gynaecological (GYN) GEC ESTRO working group (II): concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy-3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology.

Authors:  Richard Pötter; Christine Haie-Meder; Erik Van Limbergen; Isabelle Barillot; Marisol De Brabandere; Johannes Dimopoulos; Isabelle Dumas; Beth Erickson; Stefan Lang; An Nulens; Peter Petrow; Jason Rownd; Christian Kirisits
Journal:  Radiother Oncol       Date:  2006-01-05       Impact factor: 6.280

4.  Development of a model web-based system to support a statewide quality consortium in radiation oncology.

Authors:  Jean M Moran; Mary Feng; Lisa A Benedetti; Robin Marsh; Kent A Griffith; Martha M Matuszak; Michael Hess; Matthew McMullen; Jennifer H Fisher; Teamour Nurushev; Margaret Grubb; Stephen Gardner; Daniel Nielsen; Reshma Jagsi; James A Hayman; Lori J Pierce
Journal:  Pract Radiat Oncol       Date:  2016-10-20

5.  Analysis of clinical and dosimetric factors associated with treatment-related pneumonitis (TRP) in patients with non-small-cell lung cancer (NSCLC) treated with concurrent chemotherapy and three-dimensional conformal radiotherapy (3D-CRT).

Authors:  Shulian Wang; Zhongxing Liao; Xiong Wei; Helen H Liu; Susan L Tucker; Chao-Su Hu; Rodhe Mohan; James D Cox; Ritsuko Komaki
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-09-25       Impact factor: 7.038

6.  Phase II Study of Concurrent Pemetrexed, Cisplatin, and Radiation Therapy for Stage IIIA/B Unresectable Non-Small Cell Lung Cancer.

Authors:  Anthony Brade; Robert MacRae; Scott A Laurie; Andrea Bezjak; Ronald Burkes; Quincy Chu; John R Goffin; John Cho; Andrew Hope; Alex Sun; Natasha Leighl; Stephanie Capobianco; Ronald Feld; Essai Mahalingam; Anwar Hossain; Neill Iscoe; Frances A Shepherd
Journal:  Clin Lung Cancer       Date:  2015-12-21       Impact factor: 4.785

7.  Dose-volumetric parameters of acute esophageal toxicity in patients with lung cancer treated with three-dimensional conformal radiotherapy.

Authors:  Tae Hyun Kim; Kwan Ho Cho; Hong Ryull Pyo; Jin Soo Lee; Ji Youn Han; Jae Ill Zo; Jong Mog Lee; Eun Kyoung Hong; Il Ju Choi; Sung Yong Park; Kyung Hwan Shin; Dae Yong Kim; Joo Young Kim
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-07-15       Impact factor: 7.038

8.  Prevention of radiochemotherapy-induced esophagitis with glutamine: results of a pilot study.

Authors:  Manuel Algara; Nuria Rodríguez; Pedro Viñals; Martí Lacruz; Palmira Foro; Anna Reig; Jaume Quera; Joan Lozano; Enric Fernández-Velilla; Ismael Membrive; Josefa Dengra; Xavier Sanz
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-05-24       Impact factor: 7.038

Review 9.  Predicting esophagitis after chemoradiation therapy for non-small cell lung cancer: an individual patient data meta-analysis.

Authors:  David A Palma; Suresh Senan; Cary Oberije; Jose Belderbos; Núria Rodríguez de Dios; Jeffrey D Bradley; R Bryan Barriger; Marta Moreno-Jiménez; Tae Hyun Kim; Sara Ramella; Sarah Everitt; Ramesh Rengan; Lawrence B Marks; Kim De Ruyck; Andrew Warner; George Rodrigues
Journal:  Int J Radiat Oncol Biol Phys       Date:  2013-09-10       Impact factor: 7.038

10.  Radiation-Induced Esophagitis is Mitigated by Soy Isoflavones.

Authors:  Matthew D Fountain; Lisa M Abernathy; Fulvio Lonardo; Shoshana E Rothstein; Michael M Dominello; Christopher K Yunker; Wei Chen; Shirish Gadgeel; Michael C Joiner; Gilda G Hillman
Journal:  Front Oncol       Date:  2015-10-21       Impact factor: 6.244

View more
  2 in total

1.  An Analysis of Clinical Toxic Effects and Quality of Life as a Function of Radiation Dose and Volume After Lung Stereotactic Body Radiation Therapy.

Authors:  Suneetha Devpura; Aharon M Feldman; Samuel D Rusu; Essa Mayyas; Avielle Movsas; Stephen L Brown; Andrew Cook; Michael J Simoff; Zhen Sun; Mei Lu; Sean Vance; Munther I Ajlouni; M Salim Siddiqui; Indrin J Chetty; Benjamin Movsas
Journal:  Adv Radiat Oncol       Date:  2021-09-29

2.  Radiation-Induced Esophagitis in Non-Small-Cell Lung Cancer Patients: Voxel-Based Analysis and NTCP Modeling.

Authors:  Serena Monti; Ting Xu; Radhe Mohan; Zhongxing Liao; Giuseppe Palma; Laura Cella
Journal:  Cancers (Basel)       Date:  2022-04-05       Impact factor: 6.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.